Entries by arcticnovartis

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
arcticnovartis
Thu, 10/05/2023 – 07:19

Read more about Novartis to present new oncology data at ESMO 2023 dem…

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
arcticnovartis
Wed, 10/04/2023 – 07:04

Read more about Novartis executes Sandoz Spin-off, completing strategic transformatio…

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
arcticnovartis
Mon, 10/02/2023 – 07:19

Read more about Novartis…

Novartis completes divestment of ‘front of eye’ ophthalmology assets

Novartis completes divestment of ‘front of eye’ ophthalmology assets
arcticnovartis
Fri, 09/29/2023 – 16:04

Read more about Novartis completes divestment of ‘front of eye’ ophthalmology assets

Divestment includes Xiidra®, on-market tre…

Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe

Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
arcticnovartis
Tue, 09/26/2023 – 07:19

Read more about Sandoz receives European Commission approval for Tyruko® (nata…

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
arcticnovartis
Mon, 09/25/2023 – 07:19

Novartis confirms Sandoz Spin-off for October 4, 2023

Novartis confirms Sandoz Spin-off for October 4, 2023
arcticnovartis
Mon, 09/25/2023 – 07:19

Read more about Novartis confirms Sandoz Spin-off for October 4, 2023

Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs …

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
arcticnovartis
Mon, 09/18/2023 – 07:19

Read more about Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu

Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
arcticnovartis
Fri, 09/15/2023 – 11:49

Read more about Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu